CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease.

The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products.

Pioneers in medical devices. The worldwide first CE-approved DCB.

With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively.

CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices.

“Live Deserves the Best”


Health Care

Life Sciences

Medical Devices

CARDIONOVUM GmbH

Miquel Craven-Bartle Capella

Manel Martinez

Joop Meijer

Nicolas Euzet

Mark Pruefert

Marcello Gramola

Diego Squara

Paolo Silvestri

Monika Mroczkiewicz

Massimo Morero

Aleksandra Grimm

The Finance and Operations team at CARDIONOVUM GmbH is responsible for managing the company's financial planning, budgeting, and reporting. They ensure efficient operational workflows, compliance with financial regulations, and optimal resource allocation to support the development and commercialization of innovative medical devices. This team plays a crucial role in sustaining the company’s financial health and operational excellence.

Finance and Operations

Leadership Team

Finance and Operations

About

Team members

Other teams at CARDIONOVUM GmbH

Leadership Team